Ozempic Gastroparesis Attorney: Statute of Limitations for Ozempic in Florida

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Legal Guidance

The legacy of general health and science information has long served as a foundation for public understanding, offering broad insights into wellness and medical advancements. This heritage emphasizes the importance of informed decision-making and awareness of potential health impacts. Transitioning from this broad context, we now focus on a specific area of concern: the intersection of pharmaceutical exposure and legal accountability. In the realm of mass production, the widespread use of medications like Ozempic has introduced new considerations for individuals who may experience adverse effects. Specifically, exposure to Ozempic has been linked to reports of gastroparesis, a condition affecting stomach muscle function. This shift from general health education to occupational exposure concern highlights the need for clarity on legal timelines. For those in Florida who have used Ozempic and developed gastroparesis, understanding the statute of limitations is critical. This legal timeframe dictates how long an individual has to file a claim, ensuring that affected parties can seek recourse. The transition from legacy health information to this targeted legal and exposure context underscores the evolving nature of public health discourse, where historical knowledge informs current risk assessment and legal navigation.

Find Out If You Qualify for Compensation →

Understanding Ozempic and Its Link to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacological action involves slowing gastric emptying, which can lead to gastrointestinal adverse reactions. Among these, gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction—has been reported in association with Ozempic use. Clinical presentation of gastroparesis includes nausea, vomiting, early satiety, bloating, and abdominal pain, which overlap with common Ozempic side effects. Diagnosis typically involves gastric emptying scintigraphy or breath tests to confirm delayed emptying. Clinical trial data from the Ozempic prescribing information document that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo. In the pool of placebo-controlled trials, nausea was reported in 15.8% of patients on 0.5 mg and 20.3% on 1 mg, compared to 6.1% on placebo; vomiting occurred in 5.0% and 9.2% on Ozempic versus 2.3% on placebo; and diarrhea in 8.5% and 8.8% versus 1.9% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Abdominal pain was also elevated: 7.3% on 0.5 mg and 5.7% on 1 mg versus 4.6% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Constipation was reported in 5.0% on 0.5 mg and 3.1% on 1 mg versus 1.5% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation due to gastrointestinal adverse reactions was higher with Ozempic: 3.1% on 0.5 mg and 3.8% on 1 mg versus 0.4% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing 1 mg and 2 mg doses, gastrointestinal adverse reactions occurred in 30.8% on 1 mg and 34.0% on 2 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal reactions with frequency below 5% included dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanism and Risk Context for Gastroparesis

Mechanistically, GLP-1 receptor agonists like semaglutide delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can lead to prolonged gastric retention. This effect is dose-dependent and may persist with chronic use, potentially contributing to gastroparesis in susceptible individuals. The reported adverse reactions align with this mechanism, as nausea, vomiting, and abdominal pain are common manifestations of delayed gastric emptying. Regarding risk anchors, the adequacy of warnings for Ozempic-associated gastroparesis is a key consideration. The prescribing information lists gastrointestinal adverse reactions but does not explicitly mention gastroparesis as a distinct adverse event. The label notes that gastrointestinal reactions occurred more frequently with Ozempic than placebo and were dose-dependent, but it does not provide specific guidance on monitoring for gastroparesis or its long-term consequences. This may affect the ability of patients and healthcare providers to recognize and address the condition early. For affected patients in Florida, attorney-related considerations include the statute of limitations for filing a product liability claim. In Florida, the statute of limitations for personal injury claims is generally four years from the date of injury, but this can vary based on the specific circumstances, such as when the injury was discovered or should have been discovered. For claims involving inadequate warnings, the timeline may start from when the patient became aware or should have become aware of the link between Ozempic and gastroparesis. Given that Ozempic was approved in 2017 and widespread use began thereafter, patients who developed gastroparesis symptoms during or after treatment should consult with an attorney to assess their individual timeline. The timeline between exposure and documented harm is critical: gastroparesis symptoms may develop weeks to months after starting Ozempic, and diagnosis often requires specialized testing. Patients who experienced persistent nausea, vomiting, or abdominal pain while on Ozempic and were later diagnosed with gastroparesis should document the onset of symptoms, duration of Ozempic use, and any diagnostic evaluations. In summary, Ozempic use is associated with a higher incidence of gastrointestinal adverse reactions, including nausea, vomiting, and abdominal pain, which are consistent with gastroparesis. The prescribing information does not explicitly warn about gastroparesis, raising questions about the adequacy of warnings. Florida patients who developed gastroparesis after using Ozempic should be aware of the four-year statute of limitations and seek legal counsel to evaluate their case based on the timing of exposure and diagnosis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Florida?

In Florida, the statute of limitations for personal injury claims, including product liability cases related to Ozempic and gastroparesis, is generally four years from the date of injury. However, the timeline may start from when the injury was discovered or should have been discovered, especially in cases involving inadequate warnings. It is crucial to consult with an attorney to determine the specific deadline for your case.

How is gastroparesis diagnosed in relation to Ozempic use?

Gastroparesis is diagnosed through tests such as gastric emptying scintigraphy or breath tests that measure how quickly food leaves the stomach. Symptoms include nausea, vomiting, early satiety, bloating, and abdominal pain. If you experience these symptoms while taking Ozempic, it is important to seek medical evaluation and document the onset and duration of symptoms.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.